The cattle tick, Rhipicephalus microplus, is regarded as the most economically important ectoparasite of livestock globally. Control is achieved primarily through the use of acaricides. This approach is hampered by the development of resistance to commercial acaricides among cattle tick populations. Vaccination against R. microplus infestation is another technology that can be integrated for effective cattle tick control. Proteins belonging to the Kunitz-BPTI family are abundant in cattle tick salivary glands, midgut, and ovaries. These organs are attractive targets for the development of a novel cattle tick vaccine. Efficacy assessment against cattle tick infestation in bovines using a vaccine containing the recombinant form of a member of the Kunitz family from R. microplus produced in a yeast expression system is reported for the first time here. The yeast Pichia pastoris was bioengineered to produce the recombinant version of a trypsin inhibitor that is expressed in cattle tick larvae (rRmLTI). Immunization with rRmLTI afforded 32% efficacy against R. microplus. The estimated molecular weight of rRmLTI was 46 kDa. Structural homology to the native form of the larval trypsin inhibitor was documented by recognition of rRmLTI in Western-blots using polyclonal antibodies from mice immunized with cattle tick larval extract or rRmLTI. Bioinformatics analysis of the partial nucleotide and deduced amino acid sequences indicated that the rRmLTI closely resembles BmTI-6, which is a three-headed Kunitz protein present in cattle tick ovary and fat tissue.
Introduction
Ectoparasitism of cattle by the southern cattle tick, Rhipicephalus microplus, inflicts severe economic losses to the livestock industry. Cattle productivity is undermined by the direct effects of ectoparasitism and indirectly by the role R. microplus plays as vector of the infectious agents causing bovine babesiosis and anaplasmosis [1, 2] . The control of R. microplus is achieved mainly through the use of chemical acaricides [3] . However, chemical acaricides have not been utilized judiciously. This has led to the development of acaricide resistance among populations of R. microplus [4, 5] .
Vaccinating cattle with tick molecules formulated as antigens to elicit a protective immune response is a strategy proven useful for the integrated control of cattle ticks [7, 10, 36] . The benefits of using anti-tick vaccines as part of an integrated control program include a reduction in the use of acaricides, extending the useful life of acaricides by delaying the onset of resistance, reducing the incidence of R. microplus-borne diseases, and decreased production costs [6, 8, 9] . The only tick molecule currently developed and marketed as a component of an anti-tick vaccine is Bm86 from R. microplus. Bm86 is a glycoprotein expressed in eggs a few days after oviposition, unfed and blood-fed larvae, nymphs, adult males, and in the ovaries of partially engorged adult females [11] . The Bm86 gene appeared to be down-regulated in the ovaries of ticks feeding on cattle infected with B. bovis [12] . Anti-tick vaccine products based on the recombinant version of Bm86 (rBm86) were registered in Australia under the trade name TickGARD ® , and in Cuba as Gavac ® in the 1990s [13, 36] . The rBm86-based vaccines are highly efficacious against R. annulatus [38, 39] , but the level of efficacy against R. microplus varies according to characteristics of the tick population targeted and host factors among other things [14, 15] . Pen trials conducted in the state of Mato Grosso do Sul, Brazil revealed that the efficacy of Bm86-based vaccines against the Campo Grande strain of R. microplus ranged from 31 to 49% [17, 18] .
Efficacy around 99% against R. annulatus obtained with Bm86-based vaccines is an indication of the consistent high level of anti-R. microplus immunoprotection that a novel antigenic and immunogenic tick molecule, or combinations thereof, could elicit in vaccinated cattle. Such level of efficacy offers the opportunity to incorporate vaccination as a tool for the integrated eradication of cattle fever tick populations [40, 41] . The search for protective antigens that are highly efficacious against R. microplus continues. Proteinase inhibitors have received attention as a group of molecules found in ticks with potential for use as immunogens in an anti-tick vaccine. Several trypsin inhibitors that are present in the egg, larval and adult stages of R. microplus have been described [19] [20] [21] . It has been suggested that the R. microplus serine protease inhibitors may be involved in larval attachment at the bite site and blood feeding [22] . Trypsin inhibitors from R. microplus larvae purified in their native form elicited a protective immune response in vaccinated cattle yielding 72.8% efficacy, and 69.7% reduction in the number of adult female ticks completing the parasitic phase of their life cycle [22] . However, a peptide designed from one of the R. microplus larval trypsin inhibitors afforded only 18.4% immunoprotection against tick infestation in crossbred cattle [23] .
The use of recombinant trypsin inhibitors can circumvent the challenge of having to purify trypsin inhibitors in sufficient quantities to conduct cattle tick vaccination tests [21, 22] . An expressed sequence tag originally identified in R. microplus larvae was later reported to correspond to sequence amplified from ovarian tissue coding for the fragment of a Kunitz-BPTI domain protease inhibitor termed rBmTI-6 [21, 24] . The rBmTI-6 was expressed in the Pichia pastoris system and characterized as a three-headed Kunitz-bovine pancreatic trypsin inhibitor, but its ability to protect immunized cattle against tick infestation remained to be determined [21] . Here, the partial nucleotide sequence of the putative R. microplus larval trypsin inhibitor was used to produce the recombinant polypeptide in the yeast expression system to probe its immunoprotective properties [24] . Results of the cattle immunization trial and other experiments using the recombinant R. microplus larval trypsin inhibitor (rRmLTI) are also reported.
Materials and methods

Ticks
Ticks used for this study were obtained from a laboratory colony maintained at EMBRAPA Beef Cattle. This colony was established using ticks collected from bovines in ranches around Campo Grande, Matto Grosso do Sul, Brazil. Ticks were maintained under laboratory conditions for two years prior to use in the experiments reported here. Cattle were used to cycle the tick progeny. Tick stages requiring incubation were kept in the laboratory at 28 • C and 80% relative humidity. The Campo Grande cattle tick strain is susceptible to commercially available acaricides.
Transformation of Pichia pastoris with RmLTI DNA construct and sequence analysis
The expressed sequence tag (EST) coding for RmLTI (GenBank ID: CK186726 [21, 24] ) was optimized for P. pastoris codon usage, and synthesized by Epoch Biolabs, Inc. Codon optimization was done using Epoch Biolabs, Inc. proprietary software set at 15% cut off for codon efficiency. This RmLTI DNA fragment was cloned into pPICZ␣A, producing the pPICZ␣RmLTI construct. The recombinant plasmid codes for a His tag that is added to the N-terminus of the protein product. Previously described procedures were followed to produce rRmLTI in the P. pastoris expression system [25] . Alignment, similarity, and discordance comparisons based on bioinformatics techniques were conducted between predicted amino acid sequences for: rRmLTI, EST CK186726, BmTI-6 from ovarian cDNA (GenBank ID: P83606.2), and N-terminal amino acid sequence information for BmTI-A (GenBank ID: P83609), BmTI-D (GenBank ID: P83607), BmTI-2 (GenBank ID: P83603), and BmTI-3 (GenBank ID: P83604). ClustalW from the BioEdit suite was used with Vector NTI ® software (Invitrogen) as described previously to conduct the bioinformatics analyses [16] . The amino acid sequence from rRmLTI was submitted to protein function and superfamily analysis using the protein domains identifier software InterProScan [42] .
2.3. rRmLTI quantitation and purification, and murine antibody production Protein concentration in P. pastoris culture supernatant was quantified as described previously [25] . Proteins were precipitated with methanol and the precipitated proteins resuspended in denaturing binding buffer (8 M Urea, 20 mM sodium phosphate pH 7.8, 500 mM NaCl). The rRmLTI was purified using a Ni 2+ charged Ni-NTA (Qiagen, Hilden, Germany) affinity column with denaturing elution buffer (8 M Urea, 20 mM Sodium Phosphate pH 4.0, 500 mM NaCl) and the purification process monitored by 7.5% SDS-PAGE. Eluted fractions of high purity were pooled and dialyzed against PBS.
Animal care and use was conducted at EMBRAPA Beef Cattle according to institutional guidelines. Polyclonal serum against R. microplus larval extract or rRmLTI was produced using BALB/c mice as described previously [25] . The RmLTI vaccine was prepared with 500 g of rRmLTI protein resuspended in 4 mL of 150-mM Tris-HCl at pH 7.4 and emulsified with 6 mL of Montanide ISA 61 VG (Seppic, Paris). Twelve female BALB/c mice were used, which were separated into two groups of six animals. One group received the rRmLTI formulation and the other the larval extract preparation. Each mouse within the respective group was immunized with 50 g mL −1 dose −1 of rRmLTI, or 100 g mL −1 dose −1 of larval extract. Three subcutaneous doses were applied at 21-day intervals. Sera were collected 21 days after the last dose.
rRmLTI electrophoresis and Western blotting
Electrophoresis analysis was performed on material from a 10% polyacrylamide gel run with 10 L of culture supernatant per well containing 0.55 g L −1 of protein. Subsequent Western blotting analysis was performed as previously described [25] .
Pen trial, bovine serum analysis, and efficacy assessment
The rRmLTI antigen expressed in P. pastoris was adjuvated with Montanide ISA 61 VG (Seppic, Paris) and doses of 2 mL containing 100 g of the recombinant protein prepared. One-year old Holstein calves were randomly distributed into two groups of six animals each. One group was immunized with rRmLTI antigen purified and formulated as described above. The second group (negative controls) was injected with adjuvant/saline alone. Serum samples were collected and processed, and all procedures involving ticks were performed according to methods described previously [17] . Sera obtained immediately before the initial injection, and at different time points thereafter, from each of the six cattle in the vaccinated and control groups were pooled and stored in an ultralow freezer until ready for ELISA testing.
For ELISA, microtiter plates were coated with 1 g mL −1 of rRmLTI antigen in 20 mM sodium carbonate buffer (pH 9.6), 50 L per well, and incubated overnight at 4 • C. Duplicate samples of pooled sera for each group and sampling date were tested. Subsequent procedures were performed as described previously [25] .
Procedures described before were followed to assess treatment effects on tick biology and vaccine efficacy [17, 26] . Engorged female ticks dropping off of cattle from each group were collected daily for 13 days and incubated in the laboratory to obtain eggs that were pooled until 1 gram was accumulated. The egg masses obtained per collection day from several ticks in each group were incubated to determine hatching rates.
Ex vivo feeding of anti-rRmLTI IgG and assessment of tick egg eclosion rates
Serum samples from bovines immunized with rRmLTI were collected just prior to tick infestation and subjected to affinity chromatography on a protein A-Sepharose column to purify immunoglobulin G (IgG). The IgG eluted from the column resulted in a yield of 5 mg mL −1 of non-immune serum. Four groups, each consisting of ten adult female ticks, were set up for treatment. Each tick in the respective group was fed with the antibody mixture containing 0, 25, 50, or 100 g of purified IgG in 20 L by placing a capillary tube in its hypostome. The effect on egg eclosion was assessed as described previously [17] .
Statistics
Data on female reproductive parameters were analyzed using a t-test. Otherwise, differences between means were determined using one-way analysis of variance (ANOVA). Differences were considered significant when p < 0.05.
Results
Production of rRmLTI in P. pastoris expression system
Identity of the DNA insert in pPICZ␣RmLTI was confirmed by sequencing and alignment with the RmLTI clone sequence. One Mut + clone was selected and analysis of the induced recombinant protein revealed a band of approximately 46 kDa. The calculated molecular weight for rRmLTI was 37.9 kDa. It remains to be validated if post-translational modification through glycosylation, potentially adding 8-9 mannose and two N-acetyl-glucosamine molecules, may have caused the discrepancy between the calculated and observed molecular weights of the protein product in P. pastoris. Direct quantification from culture supernatants revealed rRmLTI production levels of 550 mg L −1 . Analysis of the nickel column purification product showed a protein of 46 kDa and the yield following purification was 870 mg L −1 . Western blot analysis of the rRmLTI protein was carried out with primary sera from mice (anti-R. microplus larval extract and anti-rRmLTI) and anti-His tag monoclonal antibody revealing affinity for a protein of approximately 46 kDa (Fig. 1). 
Immunoprotection against R. microplus infestation in cattle vaccinated with rRmLTI
The antibody response of cattle immunized with the vaccine formulation containing rRmLTI is shown in Fig. 2 . Antibody levels against rRmLTI peaked around 31 days after the second booster immunization. Tick infestations were established around ten days before the apparent decline in the specific antibody response commenced. A transient effect on the average weight of engorged adult female ticks dropping off of vaccinated cattle was apparent through the ninth day of the collection period (Fig. 3) . With the exception of days 2 and 4, the average weight of engorged female ticks collected from the vaccinated group was significantly lower up to day nine ( Fig. 3; p < 0.05) . Equivalence of the average engorged adult female tick weight between groups beyond day 9 of the collection period was temporally associated with the aforementioned decline in antirRmLTI antibody levels (Fig. 2) . A similar tendency was observed in the eclosion rate for eggs collected from ticks detaching from vaccinated cattle (Fig. 4) . 1  1209  818  267  210  112  161  95  90  2  661  441  254  209  138  142  98  85  3  571  588  276  209  121  143  97  86  4  521  602  285  234  145  160  98  89  5  1089  671  304  209  160  154  96  91  6  543  89  275  190  149  125  96 a Arithmetic mean ± standard deviation; p-values of t-test for independent samples are shown. b Percent reduction was calculated in relation to the control unvaccinated group: DT, adult female ticks; DW, tick weight; DO, egg laying capacity; DF, fertility. Efficacy (%) = 100 [l − (CRT × CR0 × CRF)]; where CRT: reduction in the number of adult female ticks, CRO: reduction in the egg laying capacity, CRF: reduction in fertility.
The cumulative count of engorged adult female ticks collected up to day 13 after detachment started was used to calculate the effects of vaccination with rRmLTI (Table 1) . Vaccinated cattle had 30% less ticks detaching from them than the animals injected with adjuvant only. Although egg laying capacity was unaffected, there was a significant effect associated with vaccination on tick weight and larval hatchability (Table 1 ; p < 0.05). Overall, the rRmLTI vaccine afforded 32% immunoprotection against cattle tick infestation ( Table 1) . 
Effect of purified anti-rRmLTI IgG on tick egg eclosion
The effect of the anti-rRmLTI antibody response on egg hatching was explored further ex vivo. An inverse dose-response was observed between egg hatching and the amount of IgG imbibed by the gravid tick (Fig. 5) . The viability of eggs laid by female ticks ingesting IgG antibodies from cattle vaccinated with rRmLTI was significantly compromised and hatching decreased 75.6% in eggs from ticks fed 100 g of IgG (p < 0.05). 
Identification of RmLTI as a member of the Kunitz-bovine pancreatic trypsin inhibitor family
A comparison of the DNA sequences from the EST CK186726 and the RmLTI clone optimized for codon usage in P. pastoris revealed 77% identity between the two sequences. The RmLTI DNA sequence in the yeast expression system was missing nineteen bases of the corresponding EST sequence (data not shown). Fig. 6 depicts the alignment of predicted amino acid sequences for rRmLTI, EST CK186726, BmTI-6 from ovarian cDNA, and Nterminal amino acid sequence information for BmTI-A, BmTI-D, BmTI-2, and BmTI-3. The deduced amino acid sequences between rRmLTI, EST CK186726, and BmTI-6 are 99% identical. Nucleic acid sequence coding for six additional amino acids (EAEAEF) in the N-terminus, and thirty two amino acids (VPRAAAAASFLEQK-LISEEDLNSAVDHHHHHH) in the C-terminal portion of the putative rRmLTI product was added during cloning procedures to allow insertion of a restriction site and coding sequence for the poly-His peptide.
The similarity between their partial amino acid sequences suggested that RmLTI in larvae is a member of the Kunitz-bovine pancreatic trypsin inhibitor (BPTI) family like BmTI-6 in the ovary of adult female cattle ticks. Further exploration of the putative function of RmLTI is reflected in Fig. 7 . Relevant protein signature features identified in the deduced amino acid sequence encoded in the expressed sequence tag CK186726 include three putative Kunitz-BPTI domains and two putative Kunitz proteinase inhibitor I2 conserved sites. As noted in BmTI-6, six N-glycosylation sites were present in the partial protein sequence of RmLTI. Six cysteine residues were observed within each of the three Kunitz domains, which are thought to form disulfide linkages contributing stability to the compact polypeptide in its folded form. Fig. 7 . A trypsin inhibitor in R. microplus larvae is encoded in expressed sequence tag CK186726. The amino acid sequence deduced from the RmLTI DNA clone optimized for use in P. pastoris was scanned for protein signature features using the InterProScan informatics tool. Asparagine residues (N) predicted to be N-glycosylated are marked with asterisks. A dotted line underlines Asn-Xaa-Ser/Thr codons. Cysteine residues (C) predicted to form disulfide bonds are highlighted in gray. Amino acids encompassing putative Kunitz-BPTI domains are underlined. Two predicted Kunitz proteinase inhibitor I2 conserved sites are double-underlined.
Discussion
Assessment of the efficacy against cattle tick infestation in bovines using a vaccine containing the recombinant form of a member of the Kunitz-BPTI family from R. microplus produced in the P. pastoris expression system is reported for the first time here. A specific and robust humoral immune response against rRmLTI was achieved with the vaccination protocol consisting of three immunizations, each applied every two weeks. The 32% efficacy obtained with the rRmLTI formulation reflects the significant challenge of discovering highly efficacious antigens protecting cattle against R. microplus infestation. Vaccination experiments where Bos indicus cattle were immunized with a mixture of purified larval trypsin inhibitors containing one or two Kunitz-type domains afforded 72.8% efficacy against R. microplus infestation [22] . In contrast, the level of immunoprotection obtained in crossbred cattle vaccinated with the synthetic polypeptide containing 29 aa residues derived from the N terminus of the R. microplus trypsin inhibitor A was 18.4% [23] . As the gene encoding RmLTI remains to be fully characterized, the apparent discrepancy between specific antibody levels and the low level of efficacy obtained with the rRmLTI vaccine may be due to the partial gene sequence of the EST used to produce the recombinant protein product in the yeast expression system. Alternatively, the structural and functional redundancy in proteins belonging to the Kunitz family present in R. microplus may also account for the relatively low efficacy attained with the rRmLTI vaccine.
Although binding of rRmLTI by polyclonal antibodies from mice immunized with tick larva extract indicates that the recombinant polypeptide produced in P. pastoris was as antigenic as the native form of the cognate larval trypsin inhibitor, it is possible that those antibodies recognized epitopes shared by the several trypsin inhibitors discovered in R. microplus larvae. Antiserum from cattle vaccinated with purified R. microplus trypsin inhibitors recognized rBmTI-6 produced in P. pastoris [21] . Antigenic similarity apparently extends beyond intra-specific boundaries because antiserum against the native form of R. microplus larval trypsin inhibitors cross-reacts with trypsin inhibitors identified in R. sanguineus larvae [27] . Immunogenicity of the rRmLTI is reflected in the kinetics of the bovine humoral immune response. The significant effect on the rate of larvae hatching from eggs laid by female ticks parasitizing vaccinated cattle, which was amplified by feeding female ticks with purified anti-rRmLTI IgG suggests that potentiation of the humoral response, perhaps using other adjuvants, could enhance the efficacy of a polyvalent vaccine with Kunitz inhibitors from R. microplus. Adjuvant choice was shown to influence antibody levels, which correlated with the level of inhibition on malaria parasites [28] . However, no direct correlation was observed between antibodies against rRmLTI and overall efficacy in our study. By comparison, the vast array of Kunitz type inhibitors present in R. microplus was invoked to explain the apparently small impact silencing the gene coding for boophilin, a double Kunitz type thrombin inhibitor expressed in the gut, had on egg production [29] .
Considering the purported involvement of larval trypsin inhibitors and confirmed role of other Kunitz inhibitors in blood feeding, the reduced number of female ticks detaching from vaccinated cattle may reflect the impact of bovine anti-rRmLTI antibodies on the ability of R. microplus to acquire a blood meal [20, 29] . However, the physiological roles of RmLTI and BmTI-6 remain to be determined in the larval and adult stages of the cattle tick, respectively, despite similarities in their partial nucleotide and amino acid sequences. Without knowing the function of RmLTI and BmTI-6, it remains possible that the decrease in hatching rates observed in eggs laid by female ticks fed purified IgG antibodies obtained from vaccinated cattle resulted from the effects of antibody binding to epitopes shared by rRmLTI and the native form of BmTI-6 in R. microplus ovaries.
The Kunitz family of polypeptides is one of at least 20 families belonging to the canonical type of serine protease inhibitors [30] . A characteristic of proteins belonging to this family is the Kunitz domain that can be present in single or multiple copies. At least 303 Kunitz proteins have been identified in ticks thus far and some of them can contain as many as seven Kunitz domains [31] . Cysteine patterns were used to classify Kunitz proteins into three groups to facilitate study of their evolution in the Lyme disease vector Ixodes scapularis and to expand the analysis to ticks in general [31] . Although primarily involved in proteinase inhibition, the Kunitz domain has evolved to perform other functions requiring protein-protein interactions [32] . Cattle tick ovaries, fat body, hemocytes, and midgut contain Kunitz proteins [21, 29, 33, 34] . Proteomic studies revealed the presence of Kunitz proteins that are up-regulated in ovarian tissue when R. microplus is infected with Babesia bovis [35] . A publicly available genomic database called CattleTickBase offers the opportunity to study the evolutionary history of Kunitz proteins in R. microplus [35] . It is possible that BmTI-6 and the RmLTI encoded by CK186726 are splice variants of the same gene or paralogs of the same Kunitz protein as suggested before for BmTI-A and other Kunitz proteins present in cattle tick ovary [34] .
Previous research documenting 72.8% efficacy against R. microplus infestation using purified trypsin inhibitors and the critical role Kunitz proteins play in various biological processes including proteinase inhibition warrant continued vaccine discovery research with this protein family. Production of rRmLTI in P. pastoris facilitates its use to formulate polyvalent cattle tick vaccines that include other Kunitz proteins or different antigens from R. microplus. The level of immunoprotection attained through vaccination with rRmLTI was low as compared to other novel antigens discovered recently [37, 43] . Of note are the results from vaccination using immunogenic peptides that yielded tick efficacy between 80 and 90% [44, 45] . Salivary glands, midgut, and ovaries are prime targets to disrupt cattle tick biology using vaccines and Kunitz proteins are abundant in those tissues. The use of epitopes from Kunitz proteins in combination with immunogenic portions of other tick molecules to produce a dual action vaccine could be another way to exploit the redundancy of R. microplus Kunitz inhibitors to innovate a highly efficacious cattle tick vaccine.
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